SG159529A1 - Vaccine - Google Patents

Vaccine

Info

Publication number
SG159529A1
SG159529A1 SG201000826-6A SG2010008266A SG159529A1 SG 159529 A1 SG159529 A1 SG 159529A1 SG 2010008266 A SG2010008266 A SG 2010008266A SG 159529 A1 SG159529 A1 SG 159529A1
Authority
SG
Singapore
Prior art keywords
hpv
vaccine
immunization
vaccines
virus
Prior art date
Application number
SG201000826-6A
Other languages
English (en)
Inventor
Gary Dubin
Bruce Innis
Moncef Mohammed Slaoui
Martine Anne Cecile Wettendorff
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/114,301 external-priority patent/US20050287161A1/en
Priority claimed from PCT/EP2005/006461 external-priority patent/WO2005123125A1/en
Priority claimed from US11/367,601 external-priority patent/US7858098B2/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of SG159529A1 publication Critical patent/SG159529A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG201000826-6A 2005-04-26 2006-04-24 Vaccine SG159529A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/114,301 US20050287161A1 (en) 2002-12-20 2005-04-26 Vaccine
PCT/EP2005/006461 WO2005123125A1 (en) 2004-06-16 2005-06-14 Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52
US11/367,601 US7858098B2 (en) 2002-12-20 2005-12-16 Vaccine

Publications (1)

Publication Number Publication Date
SG159529A1 true SG159529A1 (en) 2010-03-30

Family

ID=37199195

Family Applications (1)

Application Number Title Priority Date Filing Date
SG201000826-6A SG159529A1 (en) 2005-04-26 2006-04-24 Vaccine

Country Status (12)

Country Link
EP (1) EP1879614A2 (enExample)
JP (1) JP2008539182A (enExample)
KR (1) KR20080005583A (enExample)
AR (1) AR053715A1 (enExample)
AU (1) AU2006239471A1 (enExample)
CA (1) CA2606206A1 (enExample)
EA (1) EA013325B1 (enExample)
MX (1) MX2007013475A (enExample)
NO (1) NO20075185L (enExample)
SG (1) SG159529A1 (enExample)
UY (1) UY29499A1 (enExample)
WO (1) WO2006114273A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009348078B2 (en) * 2009-06-19 2013-03-14 Eyegene Inc. Vaccine for cervical cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
US6908613B2 (en) * 2000-06-21 2005-06-21 Medimmune, Inc. Chimeric human papillomavirus (HPV) L1 molecules and uses therefor
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
JP5475939B2 (ja) * 2002-12-20 2014-04-16 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｈｐｖ−１６およびｈｐｖ−１８ｌ１ｖｌｐワクチン
JP2008502633A (ja) * 2004-06-16 2008-01-31 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｈｐｖ１６およびｈｐｖ１８ならびにｈｐｖ３１、４５または５２から選ばれる少なくとも１つの別のｈｐｖ型に対するワクチン

Also Published As

Publication number Publication date
KR20080005583A (ko) 2008-01-14
AU2006239471A1 (en) 2006-11-02
EP1879614A2 (en) 2008-01-23
NO20075185L (no) 2008-01-25
AR053715A1 (es) 2007-05-16
EA200702077A1 (ru) 2008-04-28
MX2007013475A (es) 2008-04-02
JP2008539182A (ja) 2008-11-13
UY29499A1 (es) 2006-11-30
WO2006114273A3 (en) 2007-03-15
EA013325B1 (ru) 2010-04-30
CA2606206A1 (en) 2006-11-02
WO2006114273A2 (en) 2006-11-02

Similar Documents

Publication Publication Date Title
MX2012000035A (es) Antigenos de virus de sincicio respiratorio recombinantes.
MX2018010586A (es) Nanovacuna de activacion de "sting" para inmunoterapia.
MX2011000768A (es) Anticuerpos neutralizantes del virus anti-influenza a y usos de los mismos.
MX337932B (es) Proteinas f del vrs modificadas y metodos de uso de las mismas.
EP3266464A3 (en) Yeast-based therapeutic for chronic hepatitis b infection
WO2007095320A3 (en) Hpv antigens, vaccine compositions, and related methods
WO2009009759A3 (en) Yersinia pestis antigens, vaccine compositions, and related methods
WO2007095318A3 (en) Influenza antigens, vaccine compositions, and related methods
WO2007120673A3 (en) Immunogenic wt-1 peptides and methods of use thereof
CY1118090T1 (el) Αντιγονα ανασυνδυασμενου rsv
GEP20217260B (en) Antibody neutralizing human respiratory syncytial virus
MY161495A (en) Virus like particle compositions and methods of use
EP4414385A3 (en) Polyomavirus neutralizing antibodies
MA32388B1 (fr) Immunomodulation par des inhibiteurs d'iap
WO2008134643A3 (en) Trypanosoma antigens, vaccine compositions, and related methods
WO2009114560A3 (en) Compositions and methods for the therapy and diagnosis of cytomegalovirus infections
MY189495A (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
WO2007002470A3 (en) Inactivated chimeric vaccines and related methods of use
TW200731986A (en) Use of vaccines for the treatment/prevention of the transmission of pathogens
WO2018066999A3 (en) Chimeric enterovirus virus-like particles
PL1949913T3 (pl) Immunostymulująca kombinacja do profilaktyki i leczenia wirusowego zapalenia wątroby typu c
WO2003103570A3 (en) Transcutaneous immunization against papillomavirus with papillomavirus virus-like particles
SG159529A1 (en) Vaccine
WO2007120603A3 (en) Immunogenic bcr-abl peptides and methods of use thereof
MX2007013472A (es) Vacuna.